Last reviewed · How we verify
Wild-type transthyretin cardiac amyloidosis
Approved treatments
- Vyndaqel · Foldrx Pharms
Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation. - Vyndaqel · Foldrx Pharms
Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils. - Vyndaqel · Foldrx Pharms
Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils. - Vyndaqel · Foldrx Pharms
Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Wild-type transthyretin cardiac amyloidosis patent landscape — cliff calendar, originator estates, attackable patents
- Wild-type transthyretin cardiac amyloidosis treatment landscape brief
- Wild-type transthyretin cardiac amyloidosis treatment updates RSS
Frequently asked questions about Wild-type transthyretin cardiac amyloidosis
What drugs treat Wild-type transthyretin cardiac amyloidosis?
Tracked treatments include Vyndaqel.
What is the treatment for Wild-type transthyretin cardiac amyloidosis?
Standard treatment for Wild-type transthyretin cardiac amyloidosis includes Vyndaqel. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Wild-type transthyretin cardiac amyloidosis patent cliff · Wild-type transthyretin cardiac amyloidosis CI report
- Treatment: Vyndaqel · Foldrx Pharms
- Treatment: Vyndaqel · Foldrx Pharms
- Treatment: Vyndaqel · Foldrx Pharms
- Treatment: Vyndaqel · Foldrx Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing